Alyeska Investment Group
IMVT icon

Alyeska Investment Group’s Immunovant IMVT Stock Holding History

Alyeska Investment Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61,820
Closed -$2.6M – 534
2023
Q4 		$2.6M Buy
+61,820
New +$2.27M 0.02% 354
2021
Q2 		– Sell
-377,309
Closed -$6.05M – 777
2021
Q1 		$6.05M Buy
+377,309
New +$9.95M 0.08% 293

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Alyeska Investment Group's IMVT Position: Q1 2024 in Review

Alyeska Investment Group sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 61,820 shares — an estimated $2.6M sold.

Alyeska Investment Group first reported a position in IMVT in Q1 2021 and held it in 2 quarters. The position peaked at $6.05M in Q1 2021. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Alyeska Investment Group reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 61,820 Immunovant shares in Q1 2024, an estimated $2.6M.
  • Alyeska Investment Group first reported a position in Immunovant in Q1 2021 and held it in 2 quarters.
  • Alyeska Investment Group's Immunovant position peaked at $6.05M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.